WallStSmart

Circle Internet Group, Inc. (CRCL)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 2205% more annual revenue ($63.32B vs $2.75B). PFE leads profitability with a 11.8% profit margin vs -2.5%. CRCL appears more attractively valued with a PEG of 4.35. PFE earns a higher WallStSmart Score of 55/100 (C).

CRCL

Hold

42

out of 100

Grade: D

Growth: 10.0Profit: 3.0Value: 4.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.05

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CRCL.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRCL3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.9%10/10

Revenue surging 76.9% year-over-year

EPS GrowthGrowth
880.0%10/10

Earnings expanding 880.0% YoY

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CRCL4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
4.352/10

Expensive relative to growth rate

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CRCL

The strongest argument for CRCL centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 76.9% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CRCL

The primary concerns for CRCL are Price/Book, Piotroski F-Score, PEG Ratio.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CRCL profiles as a hypergrowth stock while PFE is a value play — different risk/reward profiles.

CRCL is growing revenue faster at 76.9% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor CAPITAL MARKETS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PFE scores higher overall (55/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Circle Internet Group, Inc.

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Circle Internet Group, Inc. is a platform, network, and market infrastructure for stablecoin and blockchain applications. The company is headquartered in New York, New York.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?